Eagle Pharmaceuticals, Inc.
EGRX · OTC
3/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | – | $316,610 | $171,546 | $187,802 |
| % Growth | – | 84.6% | -8.7% | – |
| Cost of Goods Sold | – | $94,936 | $42,180 | $45,465 |
| Gross Profit | – | $221,674 | $129,366 | $142,337 |
| % Margin | – | 70% | 75.4% | 75.8% |
| R&D Expenses | – | $34,088 | $51,275 | $30,785 |
| G&A Expenses | – | $98,126 | $66,822 | $75,898 |
| SG&A Expenses | – | $106,626 | $75,322 | $78,598 |
| Sales & Mktg Exp. | – | $8,500 | $8,500 | $2,700 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $140,714 | $126,597 | $109,383 |
| Operating Income | – | $80,960 | $2,769 | $32,954 |
| % Margin | – | 25.6% | 1.6% | 17.5% |
| Other Income/Exp. Net | – | -$19,527 | -$7,317 | -$10,277 |
| Pre-Tax Income | – | $61,433 | -$4,548 | $22,677 |
| Tax Expense | – | $25,791 | $4,079 | $10,688 |
| Net Income | – | $35,642 | -$8,627 | $11,989 |
| % Margin | – | 11.3% | -5% | 6.4% |
| EPS | – | 2.76 | -0.66 | 0.89 |
| % Growth | – | 518.2% | -174.2% | – |
| EPS Diluted | – | 2.73 | -0.66 | 0.87 |
| Weighted Avg Shares Out | – | 12,934 | 13,051 | 13,482 |
| Weighted Avg Shares Out Dil | – | 13,065 | 13,051 | 13,771 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $271 | $560 | $562 |
| Interest Expense | – | $4,045 | $1,635 | $2,577 |
| Depreciation & Amortization | – | $12,024 | $3,760 | $4,766 |
| EBITDA | – | $77,502 | $847 | $30,020 |
| % Margin | – | 24.5% | 0.5% | 16% |